Quality of Life in Patients With Congenital Afibrinogenemia

计划入组 250 人 · 首次发布于 2018 年 3 月 30 日

Phase 3 study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia and severe hypofibrinogenemia

计划入组 32 人

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

计划入组 24 人 · 首次发布于 2014 年 11 月 2 日

OR-102C

OR-107

OR-1896

Tres-Or Resources Ltd

Mines D`or Orbec Inc

United States

SDCL EDGE Acquisition Corporation

Cayman Islands

FDA Approves Grifols' Fesilty for Congenital Fibrinogen Deficiency Treatment

Grifols Launches FESILTY™ Fibrinogen Concentrate in the U.S. for Congenital Fibrinogen Deficiency

Suzetrigine: Hope or Hype for New Non-Opioid Pain Relief?